Status:
COMPLETED
Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )
Lead Sponsor:
Centre Hospitalier Intercommunal Creteil
Collaborating Sponsors:
Centre Hospitalier Intercommunal Villeneuve St Georges
Conditions:
HIV Patients
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective multicenter cohort study. The question arises as to whether treatment with protease inhibitors (PIs) could have a preventive role for COVID-19 infection, especially since patient...
Detailed Description
The symptomatic management of COVID-19 infections is currently at the forefront. The therapeutic efficacy of certain molecules is being evaluated in studies, in vitro and in vivo, such as remdesivir, ...
Eligibility Criteria
Inclusion
- HIV patients over 18 years of age
- Follow-up for an HIV infection 1 or 2
- Treated with antiretroviral drugs
- Resident in France during the epidemics
- No change in antiretroviral drugs during the epidemics
- No-opposition to participate to the research
Exclusion
- Patients under guardianship or curators
- Opportunistic classifying pathologies by the Control Disease Center (CDC)
- Patients unable to give a free and informed no-opposition consent to participate to the protocol
- Patients under safeguarding justice
Key Trial Info
Start Date :
May 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2021
Estimated Enrollment :
1040 Patients enrolled
Trial Details
Trial ID
NCT04357639
Start Date
May 28 2020
End Date
July 31 2021
Last Update
August 2 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CHI Créteil
Créteil, France, 94000
2
CHU Henri Mondor
Créteil, France, 94010
3
Centre hospitalier de Melun (GHSIF)
Melun, France, 77000
4
Hopital universitaire de Hotel Dieu
Paris, France, 75004